glp-1 nasal spray Compounded-GLP-1 GLP-1 (S) 10MG - Nasal

In 2024 Wegovy was the first drug approved by the FDA to treat cardiovascular disease in people with obesity

Scheme 17

Are overweight or have obesity, especially if they also have diabetes or other health risks (Trulicity and Mounjaro are not indicated for the treatment of overweight or obesity, however)

You can include efforts such as: Prior diets, medications, or weight loss programs Start and end dates for each program or medication Effectiveness, side effects, and reasons for discontinuation of previous treatments This information will be invaluable for your medical team in expediting the prior authorization process, Dr

Note any side effects and their severity to spot trends and inform dose decisions

Compared with baseline, the HbA1c decreased by 1.5% (95% confidence interval [CI], 1.27 to 1.74